ClinicalTrials.gov
ClinicalTrials.gov Menu

National Survey on Gastroesophageal Reflux Disease (GERD) Patients (LINEA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00695838
Recruitment Status : Completed
First Posted : June 12, 2008
Last Update Posted : August 6, 2009
Sponsor:
Information provided by:
AstraZeneca

Brief Summary:
The purpose of this observational study is to assess the impact of abdominal fat on severity and frequency of GERD symptoms .

Condition or disease
GERD

Study Type : Observational
Actual Enrollment : 5084 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of the Impact of Abdominal Fat on GERD Severity and GERD Frequency in General Practice
Study Start Date : January 2008
Actual Study Completion Date : December 2008

Group/Cohort
1



Primary Outcome Measures :
  1. Waist circumference [ Time Frame: Once ]

Secondary Outcome Measures :
  1. Frequency of GERD symptoms [ Time Frame: Once ]
  2. GERD impact scale [ Time Frame: Once ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
First three consecutive patients with GERD symptoms seen by GP
Criteria

Inclusion Criteria:

  • Male or female > or = 18 years old
  • Patient with symptomatic GERD
  • Without PPI or H2 antagonist treatment during the 3 previous months
  • Agree to take part in this study

Exclusion Criteria:

  • Pregnant women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00695838


  Show 1638 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Alain Castaigne, Medical Director AstraZeneca

Responsible Party: Alain Castaigne, Medical Director, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00695838     History of Changes
Other Study ID Numbers: NIS-GFR-DUM-2007/3
First Posted: June 12, 2008    Key Record Dates
Last Update Posted: August 6, 2009
Last Verified: August 2009

Keywords provided by AstraZeneca:
GERD symptoms- Waist circumference
Patients with symptomatic GERD

Additional relevant MeSH terms:
Gastroesophageal Reflux
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases